CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 78 enrolled
Drug / intervention
Interferon-Gammadrug
Likely dose
Interferon-Gamma 7 Unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05065905
NCT05065905Phase 2Completed
CompareCT.gov

A I//II Phase Study of the Efficacy and Safety of Interferon-Gamma by Subcutaneous Injection in the Complex Treatment of Patients Infected With HIV and Tuberculosis

SPP Pharmaclon Ltd.·interventional·Posted Oct 4, 2021·Updated Jan 25, 2024

In Brief

A Phase 2 clinical trial evaluating Interferon-Gamma for HIV Coinfection and 5 related conditions. Completed, enrolled 78 participants across 2 sites.

Detailed Summary

The primary purpose of this study is to assess the safety and efficacy of interferon-gamma by subcutaneous injection in complex treatment of patients with co-infection of HIV and pulmonary tuberculosis and to determine the rational of its use.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Coinfection, Aids/Hiv Problem, Tuberculosis, Pulmonary, Human Immunodeficiency Virus, Lentivirus Infections, RNA Virus Infections
CountriesRussia
CollaboratorsNorth-Western State Medical University named after I.I.Mechnikov

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 4, 2021
Enrollment StartJan 19, 2006
Primary CompletionMar 29, 2006
Study CompletionApr 6, 2006
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 4.7 years ago

Interventions

Interferon-Gammadrug

received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein